Hims & Hers melaporkan hasil kuartal pertama yang beragam

Hims & Hers Health mencatatkan pendapatan yang di bawah target pada kuartal pertama di tengah tekanan margin.

Perusahaan sedang beralih dari obat-obatan GLP-1 racikan menuju kemitraan bermerek dengan Novo Nordisk dan Eli Lilly. Perubahan ini diperkirakan akan memengaruhi margin dalam jangka pendek sekaligus menurunkan risiko hukum yang terkait dengan peracikan obat.

Artikel Terkait

Hermès reported a 6% revenue increase in the first quarter of 2026, driven entirely by higher prices amid flat volume growth. The Middle East conflict led to a 6% sales drop in that region and a double-digit decline in its US-traded shares. Analysts view the sell-off as overdone, presenting a buying opportunity for long-term investors.

Dilaporkan oleh AI

HLS Therapeutics Inc. (TSX: HLS:CA) has published a slide deck for its 2025 fourth-quarter earnings call, released on March 13, 2026, following an earnings summary dated March 12, 2026.

Palantir Technologies Inc. delivered exceptional first-quarter results, with revenue exceeding consensus estimates by 6% and earnings per share nearly 20% above forecasts. The company's revenue grew over 80% year-over-year, outpacing most tech peers. Despite the strong performance, shares did not rally amid valuation concerns.

Dilaporkan oleh AI

LVMH announced first-quarter sales rose 1% organically to €19.12 billion. Fashion and leather goods sales fell 2% to €9.25 billion, better than the prior quarter but below expectations. The Middle East conflict impacted growth by about 1 percentage point.

 

 

 

Situs web ini menggunakan cookie

Kami menggunakan cookie untuk analisis guna meningkatkan situs kami. Baca kebijakan privasi kami untuk informasi lebih lanjut.
Tolak